Vaxcyte Inc (PCVX : NASDAQ)
Common Stock
Follow PCVX
PCVX
Vaxcyte Inc
Performance
1 Day
-0.27%
1 Week
-9.79%
1 Month
-11.88%
YTD
+15.18%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$9.26B
52W High
$90.75
52W Low
$42.40
P/E Ratio
-
50 Day MA
$62.23
200 Day MA
$57.75
Beta
1.29
Dividend Yield
-
Performance history
PCVX returns since 2026
Vaxcyte Inc has traded since Jun 2026 in our data. Its deepest fall was −20.9% (Oct 2026 to Nov 2026).
1 year / yr
—
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2026*+15.2%
* Partial year (first year of data, or year to date).
$10,000 invested in PCVX
- 2026 (start of our data)$11,518
- All-time high in our data
- $74 on Oct 5, 2026 · now −20.9%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jun 2026 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past PCVX? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/19/2026 | $58.89 | $61.70 | $58.23 | $58.36 | $58.36 | 981,052 |
| 11/18/2026 | $59.16 | $59.81 | $57.60 | $58.52 | $58.52 | 1,128,282 |
| 11/17/2026 | $61.36 | $62.59 | $59.07 | $59.40 | $59.40 | 1,107,568 |
| 11/16/2026 | $63.37 | $63.79 | $61.46 | $61.61 | $61.61 | 707,760 |
| 11/13/2026 | $64.64 | $64.64 | $62.84 | $63.37 | $63.37 | 623,300 |
| 11/12/2026 | $67.60 | $67.73 | $64.62 | $64.69 | $64.69 | 1,072,464 |
| 11/11/2026 | $67.19 | $68.92 | $66.56 | $68.62 | $68.62 | 1,619,773 |
| 11/10/2026 | $67.00 | $68.18 | $65.85 | $66.36 | $66.36 | 1,268,592 |
| 11/9/2026 | $64.75 | $67.61 | $63.93 | $67.53 | $67.53 | 1,252,092 |
| 11/6/2026 | $61.92 | $65.30 | $61.14 | $63.89 | $63.89 | 1,840,900 |
Analyst Price Targets
Based on 11 analysts covering PCVX · as of Nov 20, 2026
Wall Street analysts forecast PCVX stock price to rise 99.5% over the next 12 months.
Consensus
Strong Buy4.73 / 5.00
Avg. Target
US$116.40
+99.5% Upside
Previously US$117.20 on Nov 10, 2026
Current Price
US$58.36
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCVX's historical volatility
30-Day Vol
59.9%
Annualized
90-Day Vol
66.2%
Annualized
Trend (90d)
-19.2%
Annualized drift
90d Mean
US$54.49
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$57.04 | US$46.39 – US$70.14 |
| 60 trading days | US$55.75 | US$41.62 – US$74.68 |
| 90 trading days | US$54.49 | US$38.10 – US$77.95 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-1.21B
- Profit Margin
- 0.00%
- ROE (TTM)
- -42.68%
- EPS (Diluted)
- -8.05
- Book Value
- 16.67
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About PCVX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SEAT | Vivid Seats Inc | $2.09 | +63.28% |
| MRKR | Marker Therapeutics Inc | $1.32 | +54.71% |
| ELOG | Eastern International Ltd. | $1.45 | +46.46% |
| BAER | Bridger Aerospace Group Holdings, Inc. Common Stock | $0.31 | +45.64% |
| ZKIN | ZK International Group Co Ltd | $1.65 | +32.00% |
| FLD | Fold Holdings, Inc. Class A Common Stock | $0.29 | +27.19% |
| FISN | Deep Fission, Inc. Common Stock | $3.41 | +25.83% |
| ZEO | Zeo Energy Corp. | $0.29 | +24.09% |
Free with a Wealth Awesome account
Keep analysing PCVX, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.